Postdoctoral Scientist — Neuroscience Genetics and Biomarkers
Eli Lilly and Company
Summary
At Lilly, we unite caring with discovery to make life better for people around the world. We are seeking a Postdoctoral Scientist to lead a program of integrated genetic and biomarker research in Alzheimer's disease, directly informing how we design trials, stratify patients, and develop medicines for neurodegenerative diseases.
Job description
The opportunity
This position sits at the intersection of human genetics, longitudinal biomarker science, and clinical research data in neurodegeneration. You will work with industry-leading deeply phenotype longitudinal datasets combining genetic data with fluid biomarkers, molecular and structural neuroimaging, and cognitive outcomes, drawn from both interventional study populations and independent observational cohorts. The scientific problem is how inherited genetic variation influences the rate of change along biomarker-defined disease trajectories, and what that implies for patient characterization and stratification. You will also work with established public and consortium cohorts, including population-based biomarker studies and multicenter neuroimaging initiatives, with scope to extend analyses across neurodegenerative indications.
What You Will Do
- Develop and validate polygenic and pathway-informed genetic risk models, and conduct genome-wide and targeted association analyses across multiple datasets.
- Model longitudinal biomarker trajectories using non-linear mixed-effects, latent-time, and related approaches, and test genetic modifiers of trajectory shape and rate.
- Build and benchmark multimodal prediction models for clinical progression, integrating genetic, fluid biomarker, imaging, and clinical data.
- Harmonize heterogeneous genetic and biomarker data across studies to enable replication and cross-cohort inference.
- Work cross-functionally with biomarker scientists, statisticians, and clinical colleagues, and with external academic collaborators.
- Lead first-authored manuscripts and present at international scientific meetings.
Required Qualification
- PhD (awarded or near completion) in statistical genetics, genetic epidemiology, biostatistics, applied statistics, machine learning, computational biology, or a related quantitative discipline.
- Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.
Preferred Qualifications
- Demonstrated experience with longitudinal modeling (mixed-effects, GAMMs), predictive modeling, and ML applied to biomedical data.
- Demonstrated experience with GWAS, polygenic risk score construction, and integration of omics data.
- Knowledge of Alzheimer's disease biology, biomarker science, or neurodegenerative disease.
- Experience working with clinical trial datasets or regulatory-grade data environments.
- Familiarity with neuroimaging genetics, PET or MRI data, or multimodal data integration.
- Training in causal inference methods (Mendelian randomization, mediation analysis, structural equation modelling).
- Experience with rare variant association testing from whole-exome or whole-genome sequencing (annotation, burden tests).
- Fluency in R and/or Python for statistical computing and data science.
- A record of peer-reviewed publication commensurate with career stage.
- Ability to work independently on complex analytical problems while communicating results clearly to scientists and clinicians.
Requirements
- PhD (awarded or near completion) in statistical genetics, genetic epidemiology, biostatistics, applied statistics, machine learning, computational biology, or a related quantitative discipline
- Must be authorized to work in the United States on a full-time basis
- No visa sponsorship available (including F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, L-1)
- Demonstrated experience with longitudinal modeling (mixed-effects, GAMMs), predictive modeling, and ML applied to biomedical data
- Demonstrated experience with GWAS, polygenic risk score construction, and integration of omics data
- Knowledge of Alzheimer's disease biology, biomarker science, or neurodegenerative disease
- Experience working with clinical trial datasets or regulatory-grade data environments
- Familiarity with neuroimaging genetics, PET or MRI data, or multimodal data integration
- Training in causal inference methods (Mendelian randomization, mediation analysis, structural equation modelling)
- Experience with rare variant association testing from whole-exome or whole-genome sequencing
- Fluency in R and/or Python for statistical computing and data science
- A record of peer-reviewed publication commensurate with career stage
- Ability to work independently on complex analytical problems while communicating results clearly to scientists and clinicians
Benefits
- Company Bonus
- 401(k)
- Pension
- Vacation Benefits
- Medical, Dental & Vision
- Prescription Drug Benefits
- Flexible Spending Accounts
- Life Insurance
- Death Benefits
- Time Off and Leave Benefits
- Employee Assistance Program
- Fitness Benefits
- Employee Clubs and Activities
Company overview
Eli Lilly and Company, commonly known as Lilly, is a leading American multinational pharmaceutical corporation headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company has grown into one of the world's most valuable pharmaceutical enterprises, with operations in approximately 125 countries. Lilly specializes in developing and manufacturing innovative medicines across multiple therapeutic areas, including diabetes, oncology, neuroscience, immunology, and cardiometabolic diseases. The company is renowned for its groundbreaking work in insulin production, having been the first to mass-produce insulin and later developing the first commercially available insulin product in the U.S. Lilly's current portfolio includes blockbuster medications such as Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for breast cancer, and Taltz (ixekizumab) for autoimmune conditions. With approximately 47,000 employees worldwide, Lilly maintains a strong commitment to research and development, investing heavily in scientific innovation to address some of the world's most significant health challenges. The company operates with a mission to make life better for people around the world through the discovery and delivery of innovative medicines.